Active Ingredient(s): Oprelvekin, rh-IL-11
FDA Approved: * November 25, 1997
Pharm Company: * WYETH PHARMS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Neumega Overview

Oprelvekin is recombinant interleukin eleven (IL-11),[1] a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is marketed under the trade name Neumega. Contents 1 Chemical, pharmacological and marketing data 2 Indications 3 Contraindications and precautions 4 Pregnancy 5 Lactation 6 Side effects 7 Interactions...

Read more Neumega Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Neumega Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Oprelvekin, rh-IL-11
  • Injection: 5mg
  • Vial: 5mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Neumega: (1 result)

Sorted by National Drug Code
  • 58394-004 Neumega Kit by Wyeth Biopharma Division of Wyeth Pharmaceuticals Inc., a Subsidiary of Pfizer Inc.

Other drugs which contain Oprelvekin, rh-IL-11 or a similar ingredient: (1 result)